World Journal of Urology

, Volume 27, Issue 1, pp 39–44 | Cite as

Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience

  • Tanya B. Dorff
  • Denice Tsao-Wei
  • Gus Miranda
  • Donald G. Skinner
  • John P. Stein
  • David I. Quinn
Topic Paper



To describe the tolerability of two chemotherapy regimens, gemcitabine and cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for adjuvant treatment of patients with locally advanced urothelial cancer after radical cystectomy.


The USC Department of Urology bladder cancer database was searched for subjects who received adjuvant chemotherapy following cystectomy for transitional cell carcinoma with extravesical and/or lymph node involvement, yielding 187 cases. Clinical details regarding toxicity, number of cycles administered, and cancer outcome were analyzed.


The majority of subjects had lymph node involvement (70%). Sixty-eight percent of subjects received MVAC and 32% received GC, the latter regimen was predominant after 2000. Fifty-six percent of subjects received all four planned cycles (51% GC and 58% MVAC). With a median follow-up of 11.2 years (range 1.9–19.6), 96 patients (51%) have suffered a relapse, with no significant difference between chemotherapy regimens. Median time to recurrence for the population was 3.7 years and median overall survival is 4.6 years (3.0–9.3). The median time from recurrence to death was 6.7 months and was not significantly different between MVAC and GC.


Both MVAC and GC are tolerated after cystectomy for advanced urothelial carcinoma. A significant proportion of high-risk patients survive, free of disease, beyond 10 years. At recurrence, patients previously treated with adjuvant chemotherapy have a survival that appears much shorter than patients who develop metastases in the absence of this exposure, suggesting resistance to salvage chemotherapy.


Bladder cancer Chemotherapy 


Conflict of interest statement

There is no conflict of interest.


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, THun MJ (2008) Cancer statistics 2008. CA Cancer J Clin 58:71–96. doi:10.3322/CA.2007.0010 PubMedCrossRefGoogle Scholar
  2. 2.
    Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, Skinner E, Bochner B, Thangathurai D, Mihail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMedGoogle Scholar
  3. 3.
    Ruggeri EM, Giannarelli D, Bria E, Carlini P, Felici A, Nelli F, Gallucci M, Cognetti F, Pollera CF (2006) Adjuvant chemotherapy in muscle-invasive bladder cancer: a pooled analysis from phase III studies. Cancer 106:783–788. doi:10.1002/cncr.21676 PubMedCrossRefGoogle Scholar
  4. 4.
    Grossman HB, Natale R, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarsody MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866. doi:10.1056/NEJMoa022148 PubMedCrossRefGoogle Scholar
  5. 5.
    Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala A, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A (1996) Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155:1241–1245. doi:10.1016/S0022-5347(01)66230-X PubMedCrossRefGoogle Scholar
  6. 6.
    Millikan R, Dinney C, Swanson D et al (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19(20):4005–4013PubMedGoogle Scholar
  7. 7.
    Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64(12):2448–2458. doi:10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7PubMedCrossRefGoogle Scholar
  8. 8.
    Sternberg CN, Yagoda A, Scher HI et al (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139(3):461–469PubMedGoogle Scholar
  9. 9.
    Sternberg CN, Yagoda A, Scher HI et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133(3):403–407PubMedGoogle Scholar
  10. 10.
    Moore MJ, Winquist EW, Murray N et al (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17(9):2876–2881PubMedGoogle Scholar
  11. 11.
    Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068–3077Google Scholar
  12. 12.
    Skinner DG, Daniels JR, Russell CA et al (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459–464PubMedGoogle Scholar
  13. 13.
    Kassouf W, Agarwal PK, Herr HW et al (2008) Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26:121–126. doi:10.1200/JCO.2007.12.9247 PubMedCrossRefGoogle Scholar
  14. 14.
    Stein JP, Cai J, Groshen S, Skinner DG (2003) Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 170:35–41. doi:10.1097/01.ju.0000072422.69286.0e PubMedCrossRefGoogle Scholar
  15. 15.
    Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50–54. doi:10.1016/j.ejca.2005.08.032 PubMedCrossRefGoogle Scholar
  16. 16.
    Kim SO, Jeong JY, Kim MR et al (2008) Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 14:3083–3088. doi:10.1158/1078-0432.CCR-07-4591 PubMedCrossRefGoogle Scholar
  17. 17.
    Lord RV, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286–2291PubMedGoogle Scholar
  18. 18.
    Olaussen K, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991. doi:10.1056/NEJMoa060570 PubMedCrossRefGoogle Scholar
  19. 19.
    Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11:2625–2636. doi:10.1158/1078-0432.CCR-04-1988 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Tanya B. Dorff
    • 1
    • 2
  • Denice Tsao-Wei
    • 2
  • Gus Miranda
    • 2
  • Donald G. Skinner
    • 1
  • John P. Stein
    • 1
  • David I. Quinn
    • 1
  1. 1.USC Keck School of MedicineLos AngelesUSA
  2. 2.USC Norris Cancer CenterLos AngelesUSA

Personalised recommendations